Biocells Biotechnology Co., Ltd. announced that it has received funding from ChengDu ShengNuo Biotec Co.,Ltd., Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd., Green Pine Capital Partners Co., Ltd.
October 30, 2023
Share
Biocells (Beijing) Biotechnology Co., Ltd. announced that it has raised tens of millions of yuan in a round of funding led by new investor, Green Pine Capital Partners Co., Ltd. on October 31, 2023. The transaction also included participation from new investors, Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd. and ChengDu ShengNuo Biotec Co.,Ltd.
ChengDu Sheng Nuo Biotec Co Ltd is a China-based company mainly engaged in the research and development of peptide active pharmaceutical ingredients (APIs) and preparation products. The Company's main business includes independent research and development, production and sales of peptide APIs and preparations, providing pharmaceutical research services for peptide innovative drugs, customized production services for peptide products and transfer services for peptide drug production technology for domestic and foreign pharmaceutical companies, providing original equipment manufacture processing of small molecule chemical drug levosimendan preparations and levosimendan API production, export and sales business. The Company's products target areas including immunity, digestive tract, antiviral, obstetrics and gynecology, diabetes, cardiovascular and cerebrovascular, rare diseases, orthopedics and others. The Company mainly conducts its business in domestic and foreign markets.
Biocells Biotechnology Co., Ltd. announced that it has received funding from ChengDu ShengNuo Biotec Co.,Ltd., Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd., Green Pine Capital Partners Co., Ltd.